Theratechnologies Inc. Board of Directors

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Mr. Paul Lévesque

Mr. Paul Lévesque

President, CEO & Director

Hon. Andre Dupras M.Sc.

Hon. Andre Dupras M.Sc.

Vice President of Human Resources

Mr. John Leasure

Mr. John Leasure

Global Commercial Officer

Dr. Christian Marsolais Ph.D.

Dr. Christian Marsolais Ph.D.

Senior VP & Chief Medical Officer

Mr. Jocelyn Lafond L.L.M., LL.B.

Mr. Jocelyn Lafond L.L.M., LL.B.

General Counsel & Corporate Secretary

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.